Rigel Pharmaceuticals, Inc.
DE ˙ DB ˙ US7665596034
SecurityDE:RI2 / Rigel Pharmaceuticals, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership28,108 shares
Latest Disclosed Value $ 760,040
Squarepoint Ops LLC reports 47.52% decrease in ownership of RI2 / Rigel Pharmaceuticals, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 28,108 shares of Rigel Pharmaceuticals, Inc. (DE:RI2) valued at $760,040 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 53,556 shares of Rigel Pharmaceuticals, Inc.. This represents a change in shares of -47.52% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RIGEL PHARMACEUTICALS COM 766559702 28,108 -25,448 -47.52 760 -66.86 0.0009
2026-02-13 2025-12-31 13F RIGEL PHARMACEUTICALS COM 766559702 53,556 -119,082 -68.98 2,294 -53.11 0.0024
2025-11-14 2025-09-30 13F RIGEL PHARMACEUTICALS COM 766559702 172,638 136,423 376.70 4,891 621.24 0.0049
2025-08-27 2025-06-30 13F/A-1 RIGEL PHARMACEUTICALS COM 766559702 36,215 14,135 64.02 678 70.78 0.0007
2025-08-14 2025-06-30 13F RIGEL PHARMACEUTICALS COM 766559702 36,215 14,135 678 0.0007
2025-08-27 2025-03-31 13F/A-1 RIGEL PHARMACEUTICALS COM 766559702 22,080 -41,336 -65.18 397 -62.76 0.0005
2025-05-15 2025-03-31 13F RIGEL PHARMACEUTICALS COM 766559702 22,080 -41,336 397 0.0005
2025-02-14 2024-12-31 13F RIGEL PHARMACEUTICALS COM 766559702 63,416 18,159 40.12 1,067 45.63 0.0011
2024-11-14 2024-09-30 13F RIGEL PHARMACEUTICALS COM 766559702 45,257 -35,653 -44.07 732 10.08 0.0011
2024-08-14 2024-06-30 13F RIGEL PHARMACEUTICALS COM 766559702 80,910 80,910 665 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.